RecruitingNot ApplicableNCT03675412

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

Acute Changes in Optic Nerve Head (ONH) and Macular Blood Flow After Caffeine Consumption in Glaucoma Patients and Healthy Subjects: A Quantitative Optic Coherence Tomography Angiography (OCTA) Study


Sponsor

Wills Eye

Enrollment

80 participants

Start Date

Dec 30, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.


Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying how caffeine consumption affects the tiny blood vessels in the eyes of people with glaucoma (a condition where the optic nerve is damaged due to high eye pressure) compared to people with healthy eyes, using a special type of eye scan called OCT angiography. **You may be eligible if...** - You are between 18 and 90 years old - You have been diagnosed with primary open-angle glaucoma (mild, moderate, or advanced), OR - You are a healthy person with no eye disease (for the control group) **You may NOT be eligible if...** - You have other eye or body conditions that would affect the scan results - You have more than a moderate cataract (clouding of the eye lens) - You have nystagmus (uncontrolled eye movement) - You have macular degeneration beyond very mild drusen or pigment changes - You have diabetes - You are unable to focus on a target during the scan Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTCaffeine tablet

Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.


Locations(1)

Wills Eye Glaucoma Service

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03675412


Related Trials